Lundbeck funds propel Ossianix towards Series A in 2013

A strategic investment from CNS specialist H. Lundbeck A/S will allow Ossianix to undertake preclinical proof-of-concept studies that, in turn, could permit the Philadelphia-based start-up to raise further money in a Series A round sometime in 2013, according to CEO Frank Walsh.